All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Oxurion NV

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Additional Topline Data from Positive Phase 1 Trial with THR-687

Contact the Supplier

Lead Product(s): THR-687

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 05, 2020

Details:

THR-687 is expected to enter a Phase 2 clinical trial in H2 2020. Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020.